{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:55:24Z","timestamp":1780433724359,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10928-022-09839-3","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:02:51Z","timestamp":1672855371000},"page":"45-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of exposure\u2013Clinical Dementia Rating\u2013Sum of Boxes relationship in subjects with early Alzheimer\u2019s disease from the aducanumab Phase 3 trials"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7879-5769","authenticated-orcid":false,"given":"Kumar Kandadi","family":"Muralidharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Budd","family":"Haeberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajasimhan","family":"Rajagovindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Nestorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"9839_CR1","unstructured":"Alzheimer\u2019s Association (2021) What is Alzheimer\u2019s disease? https:\/\/www.alz.org\/alzheimers-dementia\/what-is-alzheimers. Accessed 24 Aug 2021"},{"key":"9839_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297:353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994","journal-title":"Science"},{"key":"9839_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock C, Konietzko U, Streffer JR et al (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron 38:547\u2013554. https:\/\/doi.org\/10.1016\/s0896-6273(03)00294-0","journal-title":"Neuron"},{"key":"9839_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"9839_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen P, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"9839_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1750-3639.2008.00133.x","volume":"18","author":"RO Weller","year":"2008","unstructured":"Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer\u2019s disease. Brain Pathol 18:253\u2013266. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00133.x","journal-title":"Brain Pathol"},{"issue":"1","key":"9839_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/psp4.12728","volume":"11","author":"K Kandadi Muralidharan","year":"2022","unstructured":"Kandadi Muralidharan K, Tong X, Kowalski KG, Rajagovindan R, Lin L, Budd Haeberlein S, Nestorov I (2022) Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer\u2019s disease. CPT Pharmacomet Syst Pharmacol 11(1):7\u201319. https:\/\/doi.org\/10.1002\/psp4.12728","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9839_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566\u2013572. https:\/\/doi.org\/10.1192\/bjp.140.6.566","journal-title":"Br J Psychiatry"},{"issue":"2","key":"9839_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham KP, Anderson DR (2004) Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 33(2):261\u2013304. https:\/\/doi.org\/10.1177\/0049124104268644","journal-title":"Sociol Methods Res"},{"key":"9839_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/NDT.S62323","volume":"10","author":"MN Samtani","year":"2014","unstructured":"Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA (2014) Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer\u2019s subjects from the Alzheimer\u2019s Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat 10:929\u2013952. https:\/\/doi.org\/10.2147\/NDT.S62323","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9839_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.trci.2015.09.001","volume":"1","author":"MN Samtani","year":"2015","unstructured":"Samtani MN, Xu SX, Russu A et al (2015) Alzheimer\u2019s disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer\u2019s disease trials of bapineuzumab. Alzheimers Dement (NY) 1:157\u2013169. https:\/\/doi.org\/10.1016\/j.trci.2015.09.001","journal-title":"Alzheimers Dement (NY)"},{"key":"9839_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10928-014-9375-z","volume":"41","author":"DJ Conrado","year":"2014","unstructured":"Conrado DJ, Denney WS, Chen D, Ito K (2014) An updated Alzheimer\u2019s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. J Pharmacokinet Pharmacodyn 41:581\u2013598. https:\/\/doi.org\/10.1007\/s10928-014-9375-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9839_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.54","volume":"2","author":"I Delor","year":"2013","unstructured":"Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P (2013) Modeling Alzheimer\u2019s disease progression using disease onset time and disease trajectory concepts applied to CDR\u2013SOB scores from ADNI. CPT Pharmacomet Syst Pharmacol 2:e78. https:\/\/doi.org\/10.1038\/psp.2013.54","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9839_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"key":"9839_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10928-019-09632-9","volume":"46","author":"U Arshad","year":"2019","unstructured":"Arshad U, Chasseloup E, Nordgren R, Karlsson MO (2019) Development of visual predictive checks accounting for multimodal parameter distributions in mixture models. J Pharmacokinet Pharmacodyn 46:241\u2013250. https:\/\/doi.org\/10.1007\/s10928-019-09632-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9839_CR16","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2010) Nonlinear mixed effects modeling (NONMEM) version 7.1.2. ICON Development Solutions, Ellicott City. https:\/\/www.iconplc.com\/innovation\/nonmem\/. Accessed 1 July 2021"},{"key":"9839_CR17","unstructured":"R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org\/. Accessed 1 July 2021"},{"issue":"6","key":"9839_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1208\/s12248-019-0370-6","volume":"21","author":"C Hu","year":"2019","unstructured":"Hu C (2019) On the comparison of methods in analyzing bounded outcome score data. AAPS J 21(6):102. https:\/\/doi.org\/10.1208\/s12248-019-0370-6","journal-title":"AAPS J"}],"updated-by":[{"DOI":"10.1007\/s10928-023-09852-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000}}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-022-09839-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-022-09839-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-022-09839-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T10:22:29Z","timestamp":1677925349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-022-09839-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["9839"],"URL":"https:\/\/doi.org\/10.1007\/s10928-022-09839-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10928-023-09852-0","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"27 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10928-023-09852-0","URL":"https:\/\/doi.org\/10.1007\/s10928-023-09852-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kumar Kandadi Muralidharan, Xiao Tong, Samantha Budd Haeberlein, and Ivan Nestorov are employees of and hold stock and\/or stock options in Biogen (Cambridge, MA, USA). Kenneth G. Kowalski was a paid consultant of Biogen. Rajasimhan Rajagovindan is a former employee of Biogen and is currently employed by Vigil Neuroscience.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were sponsored by Biogen and were approved by Ethics Committees or Institutional Review Boards at each site and conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Guideline for Good Clinical Practice. All patients provided written informed consent. An independent data monitoring committee monitored the conduct of the trials, routinely assessed safety, and reviewed futility analysis results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}